Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC; Type 1 Diabetes TrialNet Study Group. Russell WE, et al. Among authors: muir ab. Diabetes Care. 2023 May 1;46(5):1005-1013. doi: 10.2337/dc22-2200. Diabetes Care. 2023. PMID: 36920087 Free PMC article. Clinical Trial.
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC; Type 1 Diabetes TrialNet Study Group. Libman I, et al. Among authors: muir ab. Diabetes Care. 2023 Nov 1;46(11):2035-2043. doi: 10.2337/dc23-1096. Diabetes Care. 2023. PMID: 37708415
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
Challenging assumptions about the demographics of eosinophilic gastrointestinal diseases: A systematic review.
Chehade M, Wright BL, Walsh S, Bailey DD, Muir AB, Klion AD, Collins MH, Davis CM, Furuta GT, Gupta S, Khoury P, Peterson KA, Jensen ET. Chehade M, et al. Among authors: muir ab. J Allergy Clin Immunol Glob. 2024 Apr 16;3(3):100260. doi: 10.1016/j.jacig.2024.100260. eCollection 2024 Aug. J Allergy Clin Immunol Glob. 2024. PMID: 38745866 Free PMC article.
Exploring X: barriers to care for eosinophilic esophagitis.
Thanawala SU, Klein A, Raval K, Amaro JIF, Beveridge CA, Muir AB, Falk GW, Gonzalez-Hernandez G, Lynch KL. Thanawala SU, et al. Among authors: muir ab. Dis Esophagus. 2024 May 14:doae043. doi: 10.1093/dote/doae043. Online ahead of print. Dis Esophagus. 2024. PMID: 38745432
Pathophysiology of Eosinophilic Esophagitis.
Kennedy KV, Muir AB, Ruffner MA. Kennedy KV, et al. Among authors: muir ab. Immunol Allergy Clin North Am. 2024 May;44(2):119-128. doi: 10.1016/j.iac.2023.12.001. Epub 2024 Jan 9. Immunol Allergy Clin North Am. 2024. PMID: 38575212 Review.
109 results